Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl-1,1,2,2-d4)amino]ethyl]amino]-9,10-anthracenedione
Purity: ≥99% deuterated forms (d1-d8)
Formula Markup: C22H20D8N4O6
Formula Weight: 452.52956
CAS Number: 1189974-82-0
Notes: Mitoxantrone-d8 is intended for use as an internal standard for the quantification of mitoxantrone (Item No. 14842) by GC- or LC-MS. Mitoxantrone is an inhibitor of DNA topoisomerase IIα and HIV-1 integrase (IC50s = 5.3 and 3.8 μM, respectively).{23705,23704} It intercalates into DNA in a cell-free assay when used at a concentration of 2 µM, as well as inhibits DNA synthesis and induces DNA-protein crosslinks in vitro in a concentration-dependent manner.{23705,23708} Mitoxantrone inhibits the growth of K562 leukemia and K562-derived etoposide-resistant K/VP.5 cells (IC50s = 0.42 and 1.68 µM, respectively).{23705} It also inhibits the membrane fusion of a mixed population of HEK293T cells expressing either angiotensin-converting enzyme 2 (ACE2) or the extracellular domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein, also known as surface glycoprotein.{67150} Mitoxantrone (0.2 µM) inhibits the entry of SARS-CoV-2 into Vero E6 cells. Formulations containing mitoxantrone have been used in the treatment of cancer and multiple sclerosis.
English
Deutsch
